Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kδ) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block

2017 ◽  
Author(s):  
Robert Wilson ◽  
Emily Jarvis ◽  
Mickael Montembault ◽  
Nicole Hamblin ◽  
Edith M. Hessel ◽  
...  
Keyword(s):  
Phase I ◽  
Healthy Subjects ◽  
Phase I Trial ◽  
Phosphoinositide 3 Kinase

scholarly journals A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

2017 ◽  
Vol 26 (8) ◽  
pp. 889-896 ◽  
Author(s):  
Willem Hettema ◽  
Christopher Wynne ◽  
Benjamin Lang ◽  
Mario Altendorfer ◽  
Niklas Czeloth ◽  
...  
Keyword(s):  
Phase I ◽  
Healthy Subjects ◽  
Phase I Trial ◽  
Single Blind

604: A Phase I Trial of Vaccination of Personalized Peptides for HLA-A2/A24 Positive Patients with Hormone-Refractory Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 202-202
Author(s):  
Hirotsugu Uemura ◽  
Motoyoshi Tanaka ◽  
Shigeya Uejima ◽  
Takafumi Minami ◽  
Kiyohide Fujimoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Phase I Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory
Sign in / Sign up

Export Citation Format

Share Document